{"product_id":"moffitt-cancer-center-cell-coast-conference-2024","title":"Moffitt Cancer Center Cell Coast Conference 2024","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"bbb44b8\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003ch1 class=\"product_title entry-title\"\u003eMoffitt Cancer Center Cell Coast Conference 2024\u003c\/h1\u003e\n\u003cstrong\u003e+ Include: 15 videos + 15 audios + 15 file sub vtt + 17 pdfs, size: 5.99 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: medical oncologists, hematologists, cellular therapy specialists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp data-path-to-node=\"2\"\u003eHeld in the fall of 2024, this conference was launched to spotlight the rapid evolution of cellular therapies, including \u003cb data-index-in-node=\"121\" data-path-to-node=\"2\"\u003eCAR T-cell therapy\u003c\/b\u003e, \u003cb data-index-in-node=\"141\" data-path-to-node=\"2\"\u003eTumor-Infiltrating Lymphocytes (TILs)\u003c\/b\u003e, and \u003cb data-index-in-node=\"184\" data-path-to-node=\"2\"\u003eT-cell Receptor (TCR)\u003c\/b\u003e therapies. The event, themed “Spotlight Breakthroughs in Cellular Immunotherapy,” focused on operationalizing these complex treatments for broader patient access. It provided a unique forum for discussing “real-world” data—moving beyond the controlled environment of clinical trials to examine how these therapies perform in standard clinical settings for both hematologic and solid tumor malignancies.\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"3\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"3\"\u003e+ What You Will Learn\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp data-path-to-node=\"4\"\u003eAttendees were able to:\u003c\/p\u003e\n\u003cul data-path-to-node=\"5\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,0,0\"\u003eEvaluate\u003c\/b\u003e real-world outcomes of CAR T-cell therapy in Multiple Myeloma and Lymphoma, comparing them to pivotal trial data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,1,0\"\u003eAssess\u003c\/b\u003e the operational challenges of delivering TIL therapy for metastatic melanoma and its emerging role in lung cancer.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,2,0\"\u003eIdentify\u003c\/b\u003e strategies for managing unique toxicities associated with bispecific antibodies and cellular products, such as Cytokine Release Syndrome (CRS) and neurotoxicity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,3,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,3,0\"\u003eDiscuss\u003c\/b\u003e the integration of community oncologists with academic cellular therapy centers to streamline patient referrals and long-term follow-up.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,4,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,4,0\"\u003eExamine\u003c\/b\u003e the potential of TCR therapies for solid tumors, specifically reviewing the FDA approval of afamitresgene autoleucel for synovial sarcoma.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,5,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,5,0\"\u003eAnalyze\u003c\/b\u003e the logistics of “Point of Care” CAR T manufacturing and its potential to reduce costs and wait times.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"6\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"6\"\u003e+ Event Details\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"7\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"7,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,0,0\"\u003eDate:\u003c\/b\u003e October 2024 (Inaugural Event)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"7,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,1,0\"\u003eLocation:\u003c\/b\u003e Moffitt Cancer Center, Tampa, Florida\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"8\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"8\"\u003e+ Who Should Attend\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp data-path-to-node=\"9\"\u003eThe conference was designed for the broad oncology community involved in advanced cancer care:\u003c\/p\u003e\n\u003cul data-path-to-node=\"10\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,0,0\"\u003eMedical Oncologists\u003c\/b\u003e (Academic and Community-based)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,1,0\"\u003eHematologists\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,2,0\"\u003eCellular Therapy Specialists\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,3,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,3,0\"\u003eResearch Scientists\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,4,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,4,0\"\u003eNurses and Advanced Practice Providers\u003c\/b\u003e managing immunotherapy patients\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,5,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,5,0\"\u003ePharmacists\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"11\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"11\"\u003e+ Why Attend\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"12\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,0,0\"\u003eInaugural Energy:\u003c\/b\u003e As the first event of its kind from Moffitt, it set the stage for a new “Cell Coast” hub of innovation, offering unique networking with the leaders who pioneered TIL therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,1,0\"\u003eSolid Tumor Focus:\u003c\/b\u003e Unlike many cell therapy meetings that focus solely on blood cancers, this conference placed significant emphasis on the “next frontier”—treating solid tumors like lung cancer and sarcoma with engineered cells.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,2,0\"\u003ePractical Operations:\u003c\/b\u003e The agenda included dedicated sessions on “Operational Readiness,” addressing the business and logistical hurdles (e.g., bed capacity, manufacturing delays) that clinics face when adopting these therapies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eUpdates on Approved CAR-T for Lymphoma\u003c\/li\u003e\n\u003cli\u003eCAR-T for ALL\u003c\/li\u003e\n\u003cli\u003eCAR-T Strategies for Multiple Myeloma\u003c\/li\u003e\n\u003cli\u003eBi-specifics for Myeloma\u003c\/li\u003e\n\u003cli\u003eCellular Therapies for Myeloid Malignancies\u003c\/li\u003e\n\u003cli\u003eMelanoma TILs\u003c\/li\u003e\n\u003cli\u003eSurgical Considerations for TIL Procurement\u003c\/li\u003e\n\u003cli\u003eNovel Cell Therapies for Thoracic Malignancies\u003c\/li\u003e\n\u003cli\u003eAfami-cel TCR for Sarcoma\u003c\/li\u003e\n\u003cli\u003eIntravesical TIL for Bladder Cancer\u003c\/li\u003e\n\u003cli\u003ePoint of Care CAR T Manufacturing\u003c\/li\u003e\n\u003cli\u003eReal World CAR-T for Multiple Myeloma\u003c\/li\u003e\n\u003cli\u003eInfections Occurring in our ICE T Patient Population\u003c\/li\u003e\n\u003cli\u003eCAR-T in Autoimmune Diseases\u003c\/li\u003e\n\u003cli\u003eNK Cellular Therapies\u003c\/li\u003e\n\u003cli\u003eBusiness Operations of Cellular Therapies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954538319970,"sku":"MED-AMB05616","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Moffitt-Cancer-Center-Cell-Coast-Conference-2024.jpg?v=1779379262","url":"https:\/\/meducourse.com\/products\/moffitt-cancer-center-cell-coast-conference-2024","provider":"Meducourse","version":"1.0","type":"link"}